• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Cencora’s Valuation Re‑Rating At Cencora (COR) Has Changed Its Investment Story

    Simply Wall St·07/26/2026 07:19:11
    Listen to the news
    • Recent stock screens have brought past moves in Cencora into focus, highlighting rising P/E ratios, strong multi‑year returns, and its shares trading at a discount to several intrinsic value and market‑based estimates.
    • This renewed attention on Cencora’s valuation metrics has shifted investor sentiment, as the company now screens as potentially undervalued despite its long‑term gains.
    • With Cencora now screening as potentially undervalued on several models, we’ll examine how this renewed valuation focus influences its investment narrative.

    Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

    Cencora Investment Narrative Recap

    To own Cencora, you typically need to believe its scale and relationships across pharmaceuticals can translate into resilient earnings, even as biosimilars, GLP 1s and regulatory scrutiny pressure margins. The recent valuation screens, highlighting a rising P E ratio yet discounted pricing versus several fair value estimates, do not materially change the near term picture: the key catalyst remains execution on specialty services growth, while the biggest risk is ongoing margin pressure from lower fee products and reimbursement changes.

    The most relevant recent development is Cencora’s strong Q2 2026 results, with net income of US$1,641.33 million compared with US$717.87 million a year earlier and updated 2026 revenue growth guidance of 4 percent to 6 percent. This earnings strength helps explain why valuation models now flag the shares as potentially undervalued, and it ties directly into the core catalyst of sustaining profit growth in the face of slower revenue growth and structural margin headwinds.

    Yet despite attractive screens, investors should be aware of how policy and reimbursement shifts could quickly change that picture...

    Read the full narrative on Cencora (it's free!)

    Cencora's narrative projects $393.1 billion revenue and $3.4 billion earnings by 2029.

    Uncover how Cencora's forecasts yield a $350.58 fair value, a 13% upside to its current price.

    Exploring Other Perspectives

    COR 1-Year Stock Price Chart
    COR 1-Year Stock Price Chart

    Some of the lowest estimate analysts were assuming revenue of about US$375.9 billion and earnings of roughly US$3.4 billion by 2029, which reflects a more cautious view than the current undervaluation screens and raises useful questions about how much benefit Cencora will really see from AI and automation investments.

    Explore 3 other fair value estimates on Cencora - why the stock might be worth just $350.58!

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    No Opportunity In Cencora?

    Every day counts. These free picks are already gaining attention. See them before the crowd does:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.